Skip to main content
. 2015 Apr 27;45(6):576–583. doi: 10.1093/jjco/hyv045

Figure 1.

Figure 1.

Progression-free survival through Week 24 from the start of sunitinib treatment. (A) Safety analysis population (N = 1671). (B) By relative dose intensity (RDI) during the first 6 weeks of treatment among 1618 patients with dose/duration data for this period. (C) By metastatic site at baseline. (D) By prior systemic drug treatment.